$880 Million is the total value of Rhenman & Partners Asset Management AB's 86 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | R1 RCM INC | $6,812,000 | – | 325,000 | +100.0% | 0.77% | – | |
| RPRX | New | ROYALTY PHARMA PLC | $6,306,000 | – | 150,000 | +100.0% | 0.72% | – |
| HCA | New | HCA HEALTHCARE INC | $4,202,000 | – | 25,000 | +100.0% | 0.48% | – |
| ALLO | New | ALLOGENE THERAPEUTICS INC | $3,990,000 | – | 350,000 | +100.0% | 0.45% | – |
| AGL | New | AGILON HEALTH INC | $3,602,000 | – | 165,000 | +100.0% | 0.41% | – |
| OM | New | OUTSET MED INC | $2,675,000 | – | 180,000 | +100.0% | 0.30% | – |
| NKTX | New | NKARTA INC | $2,464,000 | – | 200,000 | +100.0% | 0.28% | – |
| ARVN | New | ARVINAS INC | $2,105,000 | – | 50,000 | +100.0% | 0.24% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITEDHEALTH GROUP INC | 40 | Q3 2023 | 4.0% |
| BIOMARIN PHARMACEUTICAL INC | 40 | Q3 2023 | 5.0% |
| ALKERMES PLC | 40 | Q3 2023 | 3.3% |
| LILLY ELI & CO | 39 | Q3 2023 | 5.8% |
| CVS HEALTH CORP | 39 | Q3 2023 | 3.5% |
| INTRA-CELLULAR THERAPIES INC | 39 | Q3 2023 | 2.4% |
| EDWARDS LIFESCIENCES CORP | 39 | Q3 2023 | 1.7% |
| VERTEX PHARMACEUTICALS INC | 38 | Q3 2023 | 4.3% |
| REVANCE THERAPEUTICS INC | 38 | Q3 2023 | 0.9% |
| ABBVIE INC | 37 | Q3 2023 | 4.4% |
View Rhenman & Partners Asset Management AB's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR/A | 2023-11-13 |
| 13F-HR | 2023-11-09 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
View Rhenman & Partners Asset Management AB's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.